DAY ONE BIOPHARMACEUTICALS I (DAWN) Earnings History & Surprises

NASDAQ:DAWN • US23954D1090

21.255 USD
+0 (+0.02%)
Last: Mar 12, 2026, 10:46 AM

Past quarterly earnings results for DAY ONE BIOPHARMACEUTICALS I (DAWN), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).

Earnings Snapshot

Next Earnings Date

Upcoming
Release DateMay 1, 2026
PeriodQ1 / 2026
EPS Estimate-$0.29
Revenue Estimate55.987M

Last Reported

Most Recent
Release DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported-$0.21
EPS Surprise -35.56%
Revenue Surprise 8.44%

Beat Rate

Last 8 Quarters
31%
EPS and Revenuebeats vs estimates

Quarterly Earnings Results

EPS & Revenue History (USD)

Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.

QuarterEPSEPS EstEPS SurpriseEPS Q2QRevenueRevenue EstRevenue SurpriseRevenue Q2Q
Q4 2025 -0.21 -0.15 -35.56% 67.19% 53.718M 49.538M 8.44% 83.97%
Q3 2025 -0.19 -0.30 36.38% 48.65% 39.795M 38.964M 2.13% 98.28%
Q2 2025 -0.29 -0.36 20.33% -480.00% 33.908M 36.007M -5.83% 313.92%
Q1 2025 -0.35 -0.45 22.45% 51.39% 30.761M 30.842M -0.26% -
Q4 2024 -0.64 -0.37 -73.33% - 29.2M 28.348M 3.01% -
Q3 2024 -0.37 -0.42 11.53% 31.48% 20.07M 24.016M -16.43% -
Q2 2024 -0.05 -0.77 93.47% 91.80% 8.192M 1.042M 686.18% -
Q1 2024 -0.72 -0.68 -6.41% -22.03% - -
Q4 2023 -0.64 -0.59 -7.56% -14.29% - -
Q3 2023 -0.54 -0.61 12.11% -1.89% - -
Q2 2023 -0.61 -0.62 1.98% -1.67% - -
Q1 2023 -0.59 -0.60 2.33% -22.92% - -
Q4 2022 -0.56 -0.58 3.12% -55.56% - -
Q3 2022 -0.53 -0.54 2.70% -60.61% - -
Q2 2022 -0.60 -0.50 -20.66% 88.10% - -
Q1 2022 -0.48 -0.39 -22.23% - - -
Q4 2021 -0.36 -0.36 1.28% - - -
Q3 2021 -0.33 -0.29 -15.44% - - -
Q2 2021 -5.04 -0.32 -1,468.63% - - -
Q1 2021 - - - -
Q4 2020 - - - -
Q3 2020 - - - -
Q2 2020 - - - -
Q1 2020 - - - -

Notes

  • EPS and Revenue values are non-GAAP when available, otherwise GAAP.
  • Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
  • Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
  • Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.

Earnings Q2Q Performance Trends

EPS Historical Q2Q growth and Acceleration

DAWN EPS Q2Q GrowthDAWN EPS Q2Q GrowthEPS Q2Q Growth Q2/22 Q4/22 Q2/23 Q4/23 Q2/24 Q4/24 Q2/25 Q4/25 Q2/26 Q4/26 0 -100 -200 -300 -400

Revenue Historical Q2Q growth and Acceleration

DAWN Revenue Q2Q GrowthDAWN Revenue Q2Q GrowthRevenue Q2Q Growth Q2/25 Q3/25 Q4/25 Q1/26 Q2/26 Q3/26 Q4/26 100 200 300

Surprise distribution (Last 4 Quarters)

EPS beat statistics

EPS beat (4)
3
Average EPS beat (4)
10.90%
Max EPS beat (4)
36.38%
Min EPS beat (4)
-35.56%

Revenue beat statistics

Revenue beat (4)
2
Average Revenue beat (4)
1.12%
Max Revenue beat (4)
8.44%
Min Revenue beat (4)
-5.83%

Analysis

In the last 4 quarters, DAWN has beaten EPS estimates in 3 out of 4 releases
DAWN has beaten revenue estimates in 2 out of the last 4 releases
In the last 4 quarters, DAWN has beaten the EPS estimates by 10.9% on average.
In the last 4 quarters, DAWN has beaten the revenue estimates by 1.1% on average.
→ Find peers who consistently beat earnings by at least 10% in the last 4 quarters

DAY ONE BIOPHARMACEUTICALS I / DAWN Earnings FAQ

Can you provide the last earnings date for DAY ONE BIOPHARMACEUTICALS I?

DAY ONE BIOPHARMACEUTICALS I (DAWN) last reported earnings on 2/24/2026.


Did DAWN stock beat earnings estimates in the most recent quarter?

DAY ONE BIOPHARMACEUTICALS I (DAWN) missed EPS estimates and beat revenue estimates in the most recent quarter.


What percentage of the time does DAWN stock beat earnings estimates?

In the last 4 quarters, DAY ONE BIOPHARMACEUTICALS I (DAWN) has beaten EPS estimates in 3 out of 4 releases.